Literature DB >> 6248462

Effects of long-term blockade of angiotensin converting enzyme with captopril (SQ14,225) on hemodynamics and circulating blood volume in SHR.

H Koike, K Ito, M Miyamoto, H Nishino.   

Abstract

Male spontaneously hypertensive rats (SHR), 13 weeks old, received oral administration of captopril (SQ14,225) daily at a dose of 10 mg/kg or 30 mg/kg; or water at 2 ml/kg, for 6 weeks. Captopril suppressed the development of hypertension slightly at the lower dose and completely at the higher dose. At 6 weeks of dosing, hemodynamic parameters were measured by the tracer microsphere method and blood volume by the dilution method using 51Cr erythrocytes. Cardiac output (CO) increased and mean blood pressure decreased in a dose-dependent manner; thus, total peripheral resistance decreased. Cerebral and renal blood flows increased in a dose-dependent manner while blood flow to other organs tended to increase or remained unchanged. There was no significant differences in the circulating blood volume among the three groups. In conclusion, long-term blockade of angiotensin converting enzyme (ACE) with captopril dilated blood vessels in the whole body, especially in the brain and kidney, and lowered blood pressure without causing plasma expansion or tachycardia.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6248462     DOI: 10.1161/01.hyp.2.3.299

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  15 in total

1.  Effects of acute and chronic cilazapril treatment in spontaneously hypertensive rats.

Authors:  W Fischli; F Hefti; J P Clozel
Journal:  Br J Clin Pharmacol       Date:  1989       Impact factor: 4.335

2.  Optimization of angiotensin I-converting enzyme (ACE) inhibition by rice dregs hydrolysates using response surface methodology.

Authors:  Guo-qing He; Guo-dong Xuan; Hui Ruan; Qi-he Chen; Ying Xu
Journal:  J Zhejiang Univ Sci B       Date:  2005-06       Impact factor: 3.066

3.  Ventricular performance in spontaneously hypertensive rats (SHR) with reduced cardiac mass.

Authors:  T Natsume; M B Kardon; B L Pegram; E D Frohlich
Journal:  Cardiovasc Drugs Ther       Date:  1989-06       Impact factor: 3.727

4.  Differential systemic and regional hemodynamic profiles of four angiotensin-I converting-enzyme inhibitors in the rat.

Authors:  C Richer; M P Doussau; J F Giudicelli
Journal:  Cardiovasc Drugs Ther       Date:  1989-12       Impact factor: 3.727

5.  Comparative Growth Behaviour and Biofunctionality of Lactic Acid Bacteria During Fermentation of Soy Milk and Bovine Milk.

Authors:  Subrota Hati; Nikita Patel; Surajit Mandal
Journal:  Probiotics Antimicrob Proteins       Date:  2018-06       Impact factor: 4.609

6.  Effects of captopril on left ventricular structure and function in SHR with established hypertension.

Authors:  C A Canby; P J Palmer; K R Wall; R J Tomanek
Journal:  Basic Res Cardiol       Date:  1989 May-Jun       Impact factor: 17.165

Review 7.  Captopril: a preliminary review of its pharmacological properties and therapeutic efficacy.

Authors:  R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1980-12       Impact factor: 9.546

8.  Compared myocardial and vascular effects of captopril and dihydralazine during hypertension development in spontaneously hypertensive rats.

Authors:  J L Freslon; J F Giudicelli
Journal:  Br J Pharmacol       Date:  1983-11       Impact factor: 8.739

9.  Regression of left ventricular hypertrophy and prevention of left ventricular dysfunction by captopril in the spontaneously hypertensive rat.

Authors:  J M Pfeffer; M A Pfeffer; I Mirsky; E Braunwald
Journal:  Proc Natl Acad Sci U S A       Date:  1982-05       Impact factor: 11.205

10.  NaCl plus chitosan as a dietary salt to prevent the development of hypertension in spontaneously hypertensive rats.

Authors:  Sung Hoon Park; Noton Kumar Dutta; Min Won Baek; Dong Jae Kim; Yi Rang Na; Seung Hyeok Seok; Byoung Hee Lee; Ji Eun Cho; Geon Sik Cho; Jae Hak Park
Journal:  J Vet Sci       Date:  2009-06       Impact factor: 1.672

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.